Canopy Growth Corporation Common Shares CGC

Canopy Growth Corporation, anteriormente Tweed Marijuana Inc., es una empresa diversificada de cannabis. La Compañía, a través de sus subsidiarias Tweed Inc. (Tweed), Bedrocan Canada Inc. (Bedrocan) y Tweed Farms Inc. (Tweed Farms), se dedica a la producción y venta de marihuana legal en el mercado médico canadiense. También se enfoca en la producción y venta de marihuana en el mercado recreativo en Canadá. Sus marcas principales son Tweed y Bedrocan. Tweed es un productor con licencia de marihuana medicinal. La licencia comercial de Tweed cubre aproximadamente 168,000 pies cuadrados de sus instalaciones en Smiths Falls y le permite producir y vender aproximadamente 3,540 kilogramos de marihuana medicinal al año. La capacidad de producción de Tweed incluye más de 10 salas de cultivo en interiores controladas climáticamente. Bedrocan es un cannabis de grado médico. La instalación de producción de Bedrocan de más de 52,000 pies cuadrados en Toronto, Ontario, está licenciada e incluye más de 30 salas de cultivo vegetativo, más de tres salas de dispensación.

CGC hizo una agrupación de acciones (split inverso) de 1:10 el 20 de diciembre de 2023: cada 10 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• Zacks Investment Research 1 oct

  Canopy Growth Corporation (CGC) Stock Declines While Market Improves: Some Information for Investors

  Canopy Growth Corporation (CGC) declined 1.54% to $0.88 per share, underperforming the broader market which gained modestly. The stock has lost 7.43% over the past month. While revenue is expected to grow 22.09% year-over-year to $59.12 million, earnings are projected to worsen with an EPS of -$0.03 (down 200% from prior year). The company holds a Zacks Rank of #3 (Hold).

  

• Zacks Investment Research 1 oct

  VFF Stock Up 49% in Three Months: Is the Rally Sustainable?

  Village Farms International (VFF) shares have surged 49% in three months, driven by 15% cannabis sales growth and expanding 51% gross margins, primarily from strong European exports led by Germany. However, the company faces increasing competition from Tilray and Canopy Growth in European markets, pricing pressure from rising industry supply, and heavy dependence on Germany for export growth. While the company holds a Zacks Rank #3 (Hold), investors should await evidence of successful market diversification before committing to longer-term positions.

  

• The Motley Fool 30 sept

  Canopy Growth Is Closing in on Positive EBITDA. Should You Buy the Stock?

  Canopy Growth is approaching positive adjusted EBITDA with Q1 fiscal 2027 revenue up 13% year-over-year to $57.4 million, narrowing adjusted EBITDA losses to $2.3 million from $5.7 million. The MTL Cannabis acquisition is driving growth across Canadian medical, adult-use, and international markets, with expected $7.2 million in annual cost savings. However, free cash flow deteriorated to a $18.5 million outflow, raising concerns about cash generation despite an encouraging balance sheet with $241.4 million in cash.

  

• Zacks Investment Research 30 sept

  Investors Heavily Search Canopy Growth Corporation (CGC): Here is What You Need to Know

  Canopy Growth Corporation (CGC) is receiving significant investor attention. The stock has underperformed the broader market, declining 5.1% over the past month compared to the S&P 500's -0.4% change. While the company shows revenue growth of 18.2% for the current fiscal year and improving earnings estimates, it carries a Zacks Rank #3 (Hold) rating and trades at a premium valuation (F grade) relative to peers, suggesting near-term performance in line with the broader market.

  

• The Motley Fool 15 sept

  Tilray Brands Has Lost More Than Half of Its Value in 2026, but Here's the Bullish Case for Taking a Chance on This Highly Risky Stock

  Tilray Brands has lost over 50% of its value in 2026 and is down 95% over five years, making it a highly risky investment. However, the bullish case centers on potential U.S. marijuana legalization, which could trigger significant stock appreciation even before full legalization occurs. The company has diversified into beverages and alcohol to position itself for future U.S. market entry. While the stock could surge on legalization discussions similar to Canada's 2018 experience, investors should be aware of substantial risks and uncertainty.